elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Nivolumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Nivolumab
RIS
0.002
(Research Intensity Score)
Papers
354
Top papers
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
2022 · 2798 citations
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
2025 · 236 citations
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
2023 · 510 citations
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
2022 · 503 citations
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2019 · 3728 citations
Newest papers
Abstract PD7-10: Neo-n (neon): three-year event-free survival and ultrasensitive ctdna dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab
2026 · 3 citations
Neck Dissection and Immune Checkpoint Inhibitor Efficacy in Head and Neck Cancer: A Retrospective Study
2026 · 3 citations
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
2025 · 236 citations
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
2025 · 58 citations
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
2025 · 40 citations
A sample from the 100 top papers behind Nivolumab.
Create a free account to browse them all →
Nivolumab's history
Research intensity over time
Explore Nivolumab's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Nivolumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link